Drug interactions of HIV protease inhibitors

Drug Safety

Volumn 20, Issue 2, 1999, Pages 147-169

  Malaty, Lisa I ^a   Kuper, Jeffrey J ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 3A4; DELAVIRDINE; EFAVIRENZ; ETHINYLESTRADIOL; NEVIRAPINE; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; RIFAMYCIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TERFENADINE; UNCLASSIFIED DRUG;

DRUG METABOLISM; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; PRIORITY JOURNAL; REVIEW;

ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR;

EID: 0032987962     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199920020-00005     Document Type: Review

References (93)

1. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clin Pharmacokinet 1997; 32: 194-209
2. Lewis JS, Terriff CM, Coulston DR, et al. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clin Ther 1997; 19: 187-214
3. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 1997; 44: 190-4
4. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-11
5. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277: 145-53
6. Heylen R, Miller R. Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients. Genitourin Med 1997; 73 (Pt 2): 5-11
7. Kakuda TN, Struble KA, Piscitelli SC. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm 1998; 55: 233-54
8. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51: 701-12
9. McDonald CK, Kuritzkes DR. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med 1997; 157: 951-9
10. Oliphant CM, Bonnema SM. New advances in the pharmacological treatment of human immunodeficiency virus (HIV) infection: focus on protease inhibitors. J Pharm Practice 1997: 10: 20-51
11. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-92
12. Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother 1997; 31: 1040-58
13. Piscitelli SC, Flexner C, Minor JR, et al. Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 685-93
14. Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35: 275-91
15. Fortovase® package insert. New Jersey: Roche Laboratories Inc., 1997
16. Viracept® package insert. California: Agouron Pharmaceuticals Inc., 1997
17. Dieleman J, Gyssens IC, van der Ende MEM, et al. Urologic complaints in relation to indinavir plasma levels in HIV-infected patients [abstract no. 12372]. 12th World AIDS Conference: 1998 Jun 28-July 3; Geneva
18. Crixivan® package insert. Pennsylvania: Merck and Company Inc., 1997
19. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26: 257-60
20. Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47: 1-58
21. Invirase® package insert. New Jersey: Roche Laboratories Inc., 1998
22. Norvir® package insert. Illinois: Abbott Laboratories, 1997
23. Vanhove GF, Schapiro JM, Winters MA, et al. Patient compliance and drug failure in protease inhibitor monotherapy [letter]. JAMA 1996; 276: 1955-6
24. Acosta EP, Henry K, Weller D, et al. Indinavir pharmacokinetics and relationships between exposure and antiviral effect [abstract no. A-15]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sept 28-Oct 1; Toronto (ON)
25. Burger DM, Koopmans PP, Brinkman K, et al. Therapeutic drug monitoring of the HIV-protease inhibitor indinavir [abstract no. A-19]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sept 28-Oct 1; Toronto (ON)
26. Harris M, Durakovic C, Rae S, et al. Virologic response to indinavir/nevirapine/3TC correlates with indinavir trough concentrations [abstract no. I-173]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sept 28-Oct 1; Toronto (ON)
27. Hoetelmans RMW, Reijers MHE, Weberling GF, et al. The rate of decline of HIV-1 RNA in plasma correlates with nelfinavir concentrations in plasma [abstract no. 42259]. 12th World AIDS Conference: 1998 Jun 28-July 3; Geneva
28. Hoetelmans RMW, Heeswijk RPG, Meenhorst PL, et al. Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period [abstract no. 42261]. 12th World AIDS Conference: 1998 Jun 28-July 3; Geneva
29. Burger DM, Hoetelmans RMW, Mulder JW, et al. Low plasma levels of iadinavir (IDV) are highly predictive of virological treatment failure in patients using IDV-containing triple therapy [abstract no. 42275]. 12th World AIDS Conference: 1998 Jun 28-July 3; Geneva
30. Buss N. Saquinavir soft gel capsule (Fortovase®): pharmacokinetics and drug interactions [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL)
31. Maserati R, Villani P, Cocchi L, et al. Co-trimoxazole administered for Pneumocystis carinii pneumonia prophylaxis does not interfere with saquinavir pharmacokinetics [letter]. AIDS 1998; 12: 815-6
32. Brinkman K, Huysmans F, Burger DM. Pharmacokinetic interaction between saquinavir and cyclosporine [letter]. Ann Intern Med 1998; 129: 914-5
33. Cox SR, Ferry JJ, Batts DH, et al. Delaviridine (D) and marketed protease inhibitors (PIs): pharmacokinetic (PK) interaction studies in healthy volunteers [abstract no. 372]. 4th Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb 1; Washington (DC)
34. Data on file. DuPont Research Laboratories, 1998
35. McCrea J, Buss N, Stone J, et al. Indinavir-saquinavir single dose pharmacokinetic study [abstract no. 608]. 4th Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington (DC)
36. Merry C, Mulcahy F, Barry, M, et al. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease [letter]. AIDS 1997; 11: 268-9
37. Kravcik S, Sahai J, Kerr B, et al. Nelfinavir mesylate (NFV) increases saquinavir-soft gel capsule (SQV-SGC) exposure in HIV+ patients [abstract]. 4th Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington (DC)
38. Merry C, Barry MG, Mulcahy FM, et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997; 11: F117-20
39. Gallicano K, Sahai J, Kravcik S, et al. Nelfinavir (NFV) increases plasma exposure of saquinavir in hard gel capsule (SQV-HGC) in HIV+ patients [abstract no. 353]. 5th Conference on Retroviruses and Opportunistic Infections: 1998 Feb 1-5; Chicago (IL)
40. Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir (SQV) and nevirapine (NVP) [abstract no. 614]. 4th Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington (DC)
41. Sahai J, Stewart F, Swick L, et al. Rifabutin (RBT) reduces saquinavir (SAQ) plasma levels in HIV-infected patients [abstract no. A27]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1996 Sept 15-18; New Orleans
42. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453-64
43. Merry C, Barry MG, Mulcahy F, et al. Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients. AIDS 1998; 12: 325-7
44. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. Ann Pharmacother 1997; 31: 647
45. Rescriptor® package insert. Michigan: Pharmacia & Upjohn Company, 1997
46. Viramune® package insert. Ohio: Roxane Laboratories Inc., 1996
47. Frye R, Bertz R, Granneman GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam [abstract A59]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1997 Sept 28-Oct 1; Toronto (ON)
48. Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 1998; 64: 355-62
49. Morse GD, Shelton MJ, Hewitt RG, et al. Ritonavir (RIT) pharmacokinetics (PK) during combination therapy with delaviridine (DLV) [abstract no. 343]. 5th Conference on Retroviruses and Opportunistic Infections: 1998 Feb 1-5; Chicago (IL)
50. Shelton MJ, Hewitt RG, Adams JM, et al. Delaviridine (DLV) mesylate pharmacokinetics (PK) during combination therapy with ritonavir (RIT) [abstract A63]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sept 28-Oct 1; Toronto (ON)
51. Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of desipramine [abstract no. Mo.B.1201]. XI International Conference on AIDS: 1996 July 7-12; Vancouver
52. Cato A, Qian J, Carothers L, et al. Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients. J Acquir Immune Defic Synd 1998; 18: 466-72
53. Fiske W, Benedek IH, Joseph JL, et al. Pharmacokinetics of efavirenz (EFV) and ritonavir (RIT) after multiple oral doses in healthy volunteers [abstract no. 42269]. 12th World AIDS Conference: 1998 Jun 28-July 3; Geneva
54. Caballero-Granado FJ, Viciana P, Cordero E, et al. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient [letter]. Antimicrob Agents Chemother 1997; 41: 1207
55. Ouellet D, Hsu A, Qian J et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 1998; 46: 111-6
56. Cato A, Cao G, Hsu A, et al. Evaluation of the effect or fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos 1997; 25: 1104-6
57. Ouellet D, Hsu A, Qian J, et al. Effect of fluvoxamine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 1998; 42: 107-12
58. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42: 2784-91
59. Bertz, Wong C, Carothers L, et al. Evaluation of the pharmacokinetics of multiple dose ritonavir and ketoconazole in combination [abstract no. PIII-94]. Clin Pharmacol Ther 1998; 63: 230
60. Tseng A, Fletcher D. Interaction between ritonavir and levothyroxine [abstract no. 60571]. 12th World AIDS Conference; 1998 Jun 28-July 3; Geneva
61. Hsu A, Granneman GR, Carothers L, et al. Ritonavir does not increase methadone exposure in healthy volunteers [abstract no. 342]. 5th Conference on Retroviruses and Opportunistic Infections: 1998 Feb 1-5; Chicago (IL)
62. Kerr B, Lee C, Yuen G, et al. Overview of in vitro and in vivo drug interaction studies of nelfinavir mesylate (NFV), a new HIV-1 protease inhibitor [abstract no. 373]. 4th Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb 1; Washington (DC)
63. Cato A, Cavanaugh J, Shi H, et al. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63: 414-21
64. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events [abstract no. Mo.B. 171]. XI International Conference on AIDS; 1996 July 7-12; Vancouver (BC)
65. Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole [abstract no. Mo.B. 1197]. XI International Conference on AIDS; 1996 July 7-12; Vancouver (BC)
66. Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstract no. Mo.B.1200]. XI International Conference on AIDS; 1996 July 7-12; Vancouver (BC)
67. Gatti G, Alessandrtini A, Camera M, et al. Influence of indinavir and ritonavir on warfarin anticoagulation activity [letter]. AIDS 1998; 12: 825-6
68. Cato A, Qian J, Hsu A, et al. Multidose pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998; 42: 1788-93
69. Emmanuel A, Gillotin C, Farinotti R, et al. Atovaquone suspension and indinavir have minimal pharmacokinetic interactions [abstract no. 12384]. 12th World AIDS Conference; 1998 Jun 28-July 3; Geneva
70. Fiske WD, Mayers D, Wagner K, et al. Pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals [abstract no. 568]. 4th Conference on Retro-viruses and Opportunistic Infection: 1996 Jan 28-Feb 1; Washington (DC)
71. Ferry JJ, Herman BD, Carel BJ, et al. Pharmacokinetic drug-drug interaction study of delaviridine and indinavir in healthy volunteers. J Acquir Immune Defic Syndr 1998; 18: 252-9
72. DeWit S, Debier M, DeSmet M, et al. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1998; 42: 223-7
73. Rana KZ, Okereke CS, Melbourne KM, et al. Effect of GMCSF on the pharmacokinetics of indinavir in HIV-infected patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sept 27-27; San Diego (CA)
74. Piscitelli SC, Vogel S, Figg WD, et al. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus. Pharmacother 1998; 18: 1212-6
75. Squires K, Riddler S, Havlir D. et al. Co-administration of indinavir (IDV) 1000mg with escalating nelfinavir (NFV) does in a twice daily regimen: preliminary safety, pharmacokinetic (PK) and anti-viral activity [abstract no. 464]. 36th Annual Meeting of the Infectious Diseases Society of America. 1998 Nov 11-14, Denver (CO)
76. Murphy R, Gagnier P, Lamson M. et al. Effect of nevirapine (NVP) on pharmacokinetics (PK) of indinavir (IDV) and ritonavir (RTV) in HIV-1 patients [abstract no. 374]. 4th Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington (DC)
77. Cox SR, Schneck DW, Herman BD, et al. Delaviridine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract no. 345]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL)
78. Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between efavirenz (EFV) and nelfinavir mesylate (NFV) in healthy volunteers [abstract no. 349]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL)
79. Merry C, Barry MG, Mulcahy FM, et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998; 12: 1163-7
80. Skowron G, Leoung G, Dusek A, et al. Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): preliminary safety, activity and pharmacokinetic (PK) interactions [abstract no. 350]. 5th Conference on Retroviruses and Opportunistic Infections: 1998 Feb 1-5; Chicago (IL)
81. Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine [editorial]. AIDS 1998; 12: 1243-4
82. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society - USA Panel. JAMA 1997; 277: 1962-9
83. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-5): 1-82
84. Merrill D, Manion DJ, Chou TC, et al. Antagonism between human immunodeciency virus type 1 protease inhibitors indinavir and saquinavir in vitro. J Infect Dis 1997; 176: 265-8
85. Hsu A, Granneman R, Heath-Chiozzi M, et al. Indinavir can be taken with regular meals when administered with ritonavir [abstract no. 22361]. 12th World AIDS Conference: 1998 Jun 28-July 3; Geneva
86. Havlir DV, Riddler S, Squires K, et al. Co-administration of indinavir (IDV) and nelfinavir (NFV) in a twice daily regimen: preliminary, safety, pharmacokinetic and anti-viral activity results [abstract no. 393]. 5th Conference on Retroviruses and Opportunistic Infections: 1998 Feb 1-5; Chicago (IL)
87. Sadler BM, Eron J, Wakeford J, et al. Pharmacokinetics of 141W94 and indinavir (IDV) after single-dose coadministration in HIV-positive volunteers [abstract no. A56]. 4th Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington (DC)
88. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41: 654-60
89. Sadler B, Gillotin C, Chittick GE, et al. Pharmacokinetic drug interactions with amprenavir [abstract no. 12389]. 12th World AIDS Conference: 1998 Jun 28-July 3; Geneva
90. Polk RE Israel DS, Pastor A, et al. Effects of clarithromycin (CLR) on the pharmacokinetics of amprenavir (APV). 38th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1998 Sept 24-28; San Diego (CA)
91. Kumar GN, Jayanti V, Johnson MK, et al. Increased bioavailability and plasma levels of the HIV-1 protease inhibitor ABT-378 in rats due to inhibition of the in vivo metabolism by ritonavir [abstract no. 207]. 4th Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28-Feb 1; Washington (DC)
92. Van Cleef GF, Fisher EJ, Polk RE. Drug interaction potential with inhibitors of HIV protease. Pharmacother 1997; 17: 774-8
93. Preston SL, Postelnick M, Purdy BD, et al. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy. AIDS 1998; 12: 228-30.